Novel RNA-Targeting Gene Therapy Shows Promise for Neuromuscular, Retinal Diseases

Video

The CEO of Locanabio shares details of 2 presentations the company is making this week at the 24th Annual Meeting of the American Society of Gene & Cell Therapy.

RNA-targeting gene therapy company Locanabio is debuting new data this week from 2 of their pipeline initiatives in neuromuscular and retinal diseases. The preclinical research highlights the company's novel approach to gene therapy, which involves delivering RNA-binding protein-based systems that correct dysfunctional RNA.

In an interview with GeneTherapyLive, Locanabio chief executive officer James Burns, PhD, shared details of the 2 presentations being shared at the 24th Annual Meeting of the American Society of Gene & Cell Therapy, the first which includes preclinical in vivo data demonstrating the safety and efficacy of their novel adeno-associated virus serotype 9-delivered PUF RNA-binding protein system for the elimination of toxic CUG repeats in a mouse model of myotonic dystrophy type 1. The second presentation centers around the company's CRISPR/Cas13d gene therapy system for the treatment of Usher syndrome type 2.

Related Videos
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
© 2024 MJH Life Sciences

All rights reserved.